次に

自動再生

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

0 ビュー • 07/14/23
シェア
埋め込む
administrator
administrator
加入者
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

もっと見せる
0 コメント sort 並び替え
フェイスブックのコメント

次に

自動再生